Disclosing the involvement of proteases in an eczema murine animal model: Perspectives for protease inhibitor-based therapies

Cruz-Silva, Ilana; Nunes, Viviane Abreu; Rydlewski, Mariana; Gozzo, Andrezza Justino; Praxedes-Garcia, Priscila; Carbonel, Adriana Aparecida Ferraz; Tanaka, Aparecida S.; Araújo, Mariana da Silva

doi:10.1016/j.biochi.2021.12.003

Cited by 2 publications

(2 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pH of skin is normally acidic and limits the protease activity (more active in basic medium). In AD, the skin pH is increased and consequently reflects in the increased activity of serine protease [ 17 ].…”

Section: Barrier Function In the Pathogenesis Of Atopic Dermatitismentioning

confidence: 99%

“…Following the matrix degradation and loss of intercellular contacts, NE appears to participate in the inflammatory features of eczematous diseases resulting in spongiosis and desquamation. Particularly, NE activity has been shown to be absent in the skin of healthy individuals, whereas a massive increase in its action has been demonstrated in the skin of patients with allergic contact (55-fold average) and atopic dermatitis (35-fold), the most common form of eczema [ 17 ].…”

Section: Barrier Function In the Pathogenesis Of Atopic Dermatitismentioning

confidence: 99%

See 1 more Smart Citation

Challenges of current treatment and exploring the future prospects of nanoformulations for treatment of atopic dermatitis

Kakkar,

Saini,

Singh

2023

Pharmacol. Rep

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a predominant and deteriorating chronic inflammation of the skin, categorized by a burning sensation and eczematous lesions in diverse portions of the body. The treatment of AD is exclusively focused to limit the itching, reduce inflammation, and repair the breached barrier of the skin. Several therapeutic agents for the treatment and management of AD have been reported and are in use in clinics. However, the topical treatment of AD has been an unswerving challenge for the medical fraternity owing to the impaired skin barrier function in this chronic skin condition. To surmount the problems of conventional drug delivery systems, numerous nanotechnology-based formulations are emerging as alternative new modalities for AD. Latter enhances the bioavailability and delivery to the target disease site, improves drug permeation and therapeutic efficacy with reduced systemic and off-target side effects, and thus improves patient health and promotes compliance. This review aims to describe the various pathophysiological events involved in the occurrence of AD, current challenges in treatment, evidence of molecular markers of AD and its management, combinatorial treatment options, and the intervention of nanotechnology-based formulations for AD therapeutics. Graphical abstract

show abstract

Section: Barrier Function In the Pathogenesis Of Atopic Dermatitismentioning

confidence: 99%

Section: Barrier Function In the Pathogenesis Of Atopic Dermatitismentioning

confidence: 99%

Challenges of current treatment and exploring the future prospects of nanoformulations for treatment of atopic dermatitis

Kakkar,

Saini,

Singh

2023

Pharmacol. Rep

View full text Add to dashboard Cite

show abstract

Proteolytic and Antiproteolytic Activity in the Skin: Gluing the Pieces Together

Peled,

Sprecher

2024

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Disclosing the involvement of proteases in an eczema murine animal model: Perspectives for protease inhibitor-based therapies

Cited by 2 publications

References 79 publications

Challenges of current treatment and exploring the future prospects of nanoformulations for treatment of atopic dermatitis

Challenges of current treatment and exploring the future prospects of nanoformulations for treatment of atopic dermatitis

Proteolytic and Antiproteolytic Activity in the Skin: Gluing the Pieces Together

Contact Info

Product

Resources

About